A Prospective, Randomized, Open-label Study of the Investigation of Peginterferon Alfa-2a on Optimal in Chronic Hepatitis B Patients Who Have a High Risk of HCC

Trial Profile

A Prospective, Randomized, Open-label Study of the Investigation of Peginterferon Alfa-2a on Optimal in Chronic Hepatitis B Patients Who Have a High Risk of HCC

Active, no longer recruiting
Phase of Trial: Phase IV

Latest Information Update: 08 May 2017

At a glance

  • Drugs Peginterferon alfa-2a (Primary) ; Adefovir; Entecavir; Tenofovir
  • Indications Hepatitis B; Liver cirrhosis
  • Focus Therapeutic Use
  • Most Recent Events

    • 23 Mar 2017 New trial record
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top